Biopharm America Digital, September 21-24, 2020.

Xplico will be present at BioPharm America Digital on September 21^st to 24^th 2020.

BioPharm America attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts and it’s the perfect opportunity to engage with global life science partners. BioPharm America is where biotech industry partnerships get started.

For this year’s digital event, BioPharm America will focus on innovation and investing, with the added collaboration of a number of diverse partners, whose unique offerings include live and recorded panel discussions, fireside chats, and company presentations.

(August 2020)

Bio Europe Digital, 26-29 October, 2020.

Engage with Xplico and global life science partners at BIO-Europe Digital, on October 26^th to 29^th 2020.

BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. In addition to productive partnering, BIO-Europe offers high level workshops, panels and company presentations. Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.

Please contact us to book a meeting, either during the conference or at a time convenient for you, to discuss how you can benefit from our valuation services.

(August 2020)

Nordic Life Science Days, Malmö, Sweden, April 20-21, 2021.

Xplico was planning on attending the Nordic Life Science Days in Malmö, Sweden, in September 2020, but due to the COVID-19 outbreak the event has been postponed to April 2021.

NLS Days is the largest Nordic partnering conference dedicated to the life science industry. NLS Days offers networking and knowledge for anyone interested in the Nordic life science, biotech, pharma, medical devices and e-health business. It’s a space for meaningful encounters, with one-on-one meetings being one of the main features. Additionally, the high quality of topics and presenters provide insight into the most recent trends in science and business.

(May 2020)

Xplico elected a Gazelle Company for the 4th year in a row

We are proud to announce that Xplico has been elected a Gazelle company for the 4^th year in a row.

The election is organized by the Danish financial newspaper Børsen, and the requirements to become a Gazelle company are tough. A Gazelle business is continuously growing and, as a minimum, doubles its revenue or gross profit over four fiscal years, while maintaining positive growth throughout the years.

It is quite impressive that we have been able to live up to this four years in a row and we express our gratitude to our customers because without their continuous support and trust this would not have been possible.

(October 2019)

The new Xplico Evaluator template is now released

Xplico proudly releases a new and enhanced version of Xplico Evaluator, our valuation tool, available for all our subscription customers.

Many things have been changed behind the scene, with only a few changes in the way the assumptions are entered. The new version can handle more advanced Deal Terms and it has more features as well as additional outputs.

(June 2019)

Publication of the Xplico Valuation Survey

(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

Read the full article

(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

Read the full article

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

Read the interview

(June 2018)